Advertisement

PharmacoEconomics & Outcomes News

, Volume 842, Issue 1, pp 32–32 | Cite as

Voretigene neparvovec good value in inherited retinal disease

Meeting report
  • 5 Downloads

References

  1. 1.
    Cariou C, et al. Cost-Effectiveness Analysis of Voretigene Neparvovec Versus Best Supportive Care in Patients with Rpe65-Mediated Inherited Retinal Dystrophy- a French Healthcare System Perspective. 22nd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. CC3, 2 Nov 2019. Available from: URL: https://www.ispor.org/conferences-education/conferences/upcoming-conferences/ispor-europe-2019/program/program
  2. 2.
    Ploug U. Cost-Effectiveness of Voretigene Neparvovec for Vision Loss Due to Biallelic Rpe65-Mediated Inherited Retinal Disease in a Danish Setting. 22nd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : (plus oral presentation) abstr. PRO29, 2 Nov 2019. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/euro2019-3122/98088

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations